{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:11:19Z","timestamp":1762459879900,"version":"3.44.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.clinbiochem.2020.06.009","type":"journal-article","created":{"date-parts":[[2020,6,14]],"date-time":"2020-06-14T17:19:10Z","timestamp":1592155150000},"page":"45-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Usefulness of estimated average glucose (eAG) in glycemic control and cardiovascular risk reduction"],"prefix":"10.1016","volume":"84","author":[{"given":"Dandan","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinbiochem.2020.06.009_b0005","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1034\/j.1600-0420.2000.078004374.x","article-title":"Screening and prevention of diabetic blindness","volume":"78","author":"Stef\u00e1nsson","year":"2000","journal-title":"Acta Ophthalmol. Scand."},{"key":"10.1016\/j.clinbiochem.2020.06.009_b0010","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1525-139X.2010.00708.x","article-title":"Transplantation in diabetic kidney failure patients: modalities, outcomes, and clinical management","volume":"23","author":"Luan","year":"2010","journal-title":"Semin. Dial."},{"key":"10.1016\/j.clinbiochem.2020.06.009_b0015","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s11892-018-1116-z","article-title":"Revisiting the diabetes-heart failure connection","volume":"18","author":"Wallner","year":"2018","journal-title":"Curr. Diab. Rep."},{"key":"10.1016\/j.clinbiochem.2020.06.009_b0020","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/dmrr.2634","article-title":"Lower-limb amputation following foot ulcers in patients with diabetes: classification systems, external validation and comparative analysis","volume":"31","author":"Monteiro-Soares","year":"2015","journal-title":"Diabetes Metab. Res. Rev."},{"key":"10.1016\/j.clinbiochem.2020.06.009_b0025","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.diabres.2018.02.023","article-title":"IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045","volume":"138","author":"Cho","year":"2018","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.clinbiochem.2020.06.009_b0030","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1399-5448.2008.00472.x","article-title":"Good glycemic control remains crucial in prevention of late diabetic complications\u2013the Link\u00f6ping Diabetes Complications Study","volume":"10","author":"Nordwall","year":"2009","journal-title":"Pediatr Diabetes"},{"key":"10.1016\/j.clinbiochem.2020.06.009_b0035","doi-asserted-by":"crossref","unstructured":"Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329 (1993) 977\u2013986.","DOI":"10.1056\/NEJM199309303291401"},{"key":"10.1016\/j.clinbiochem.2020.06.009_b0040","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.clinbiochem.2020.06.009_b0045","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1093\/clinchem\/45.9.1596","article-title":"In vitro diagnostics in diabetes: meeting the challenge","volume":"45","author":"Turner","year":"1999","journal-title":"Clin. Chem."},{"key":"10.1016\/j.clinbiochem.2020.06.009_b0050","doi-asserted-by":"crossref","unstructured":"Cas Weykamp, W. Garry John, Andrea Mosca, A review of the challenge in measuring hemoglobin HbA1c, J. Diabetes Sci. Technol. 3 (2009) 439\u2013445.","DOI":"10.1177\/193229680900300306"},{"key":"10.1016\/j.clinbiochem.2020.06.009_b0055","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2337\/dc08-0545","article-title":"HbA1c-derived average glucose study group. Translating the HBA1C assay into estimated average glucose values","volume":"31","author":"Nathan","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinbiochem.2020.06.009_b0060","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1046\/j.1464-5491.2000.00232.x","article-title":"Education integrated into structured general practice care for type 2 diabetic patients results in sustained improvement of disease knowledge and self-care","volume":"17","author":"Van den Arend","year":"2000","journal-title":"Diabet. Med."},{"key":"10.1016\/j.clinbiochem.2020.06.009_b0065","doi-asserted-by":"crossref","first-page":"816","DOI":"10.2337\/diacare.28.4.816","article-title":"The relationship between knowledge of recent HbA1c values and diabetes care understanding and self-management","volume":"28","author":"Heisler","year":"2005","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1016\/j.clinbiochem.2020.06.009_b0070","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.2337\/dc10-S011","article-title":"Standards of medical care in diabetes\u20132010","volume":"33","author":"American Diabetes Association","year":"2010","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1016\/j.clinbiochem.2020.06.009_b0075","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.2337\/dc11-S011","article-title":"Standards of medical care in diabetes\u20132011","volume":"34","author":"American Diabetes Association","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinbiochem.2020.06.009_b0080","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.clinbiochem.2012.05.016","article-title":"Position statement of the Canadian Society of Clinical Chemists and Canadian Association of Medical Biochemists on hemoglobin HbA1c measurement and reporting","volume":"45","author":"Oleschuk","year":"2012","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.clinbiochem.2020.06.009_b0085","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1373\/clinchem.2009.138669","article-title":"Point: the reporting of estimated glucose with hemoglobin HbA1c","volume":"56","author":"Sacks","year":"2010","journal-title":"Clin. Chem."},{"key":"10.1016\/j.clinbiochem.2020.06.009_b0090","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1373\/clinchem.2009.138677","article-title":"Counterpoint: the reporting of estimated glucose with hemoglobin HbA1c","volume":"56","author":"Young","year":"2010","journal-title":"Clin. Chem."},{"key":"10.1016\/j.clinbiochem.2020.06.009_b0095","unstructured":"College of American Pathologists Survey GH2-B Participant summary, November 2013."},{"key":"10.1016\/j.clinbiochem.2020.06.009_b0100","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1001\/archinte.159.22.2661","article-title":"Scandinavian Simvastatin Survival Study Group. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses from the Scandinavian Simvastatin Survival Study","volume":"159","author":"Haffner","year":"1999","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.clinbiochem.2020.06.009_b0105","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1161\/01.CIR.98.23.2513","article-title":"Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial","volume":"98","author":"Goldberg","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.clinbiochem.2020.06.009_b0110","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Heart Protection Study Collaborative Group","volume":"361","author":"Collins","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.clinbiochem.2020.06.009_b0115","doi-asserted-by":"crossref","first-page":"886","DOI":"10.2337\/diacare.15.7.886","article-title":"Lipid and lipoprotein levels in patients with IDDM: Diabetes Control and Complications Trial Experience","volume":"15","author":"DCCT Research Group","year":"1992","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinbiochem.2020.06.009_b0120","doi-asserted-by":"crossref","unstructured":"Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol. 75 (1995) 894-903.","DOI":"10.1016\/S0002-9149(99)80683-3"},{"key":"10.1016\/j.clinbiochem.2020.06.009_b0125","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1001\/archinte.158.22.2485","article-title":"Effect of intensive glycemic control on fibrinogen, lipids, and lipoproteins: Veterans Affairs Cooperative Study in Type II Diabetes Mellitus","volume":"158","author":"Emanuele","year":"1998","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.clinbiochem.2020.06.009_b0130","doi-asserted-by":"crossref","unstructured":"J.B. Buse, S.C. Bain, J.F.E. Mann, M.A. Nauck, S.E. Nissen, S. Pocock, N.R. Poulter, R.E. Pratley, M. Linder, T. Monk Fries, D.D. \u00d8rsted, B. Zinman, LEADER Trial Investigators. Cardiovascular risk reduction with liraglutide: an exploratory mediation analysis of the LEADER trial. Diabetes Care. May 4 (2020) dc192251. doi: 10.2337\/dc19-2251. Online ahead of print.","DOI":"10.2337\/figshare.12106860.v1"},{"key":"10.1016\/j.clinbiochem.2020.06.009_b0135","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes \u2013 2020. Diabetes Care 43(Suppl 1) (2020) S66\u2013S76.","DOI":"10.2337\/dc20-S006"},{"key":"10.1016\/j.clinbiochem.2020.06.009_b0140","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1177\/193229680900300516","article-title":"Clinically significant disagreement between mean blood glucose and estimated average glucose in two populations: implications for diabetes management","volume":"3","author":"Chalew","year":"2009","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.clinbiochem.2020.06.009_b0145","doi-asserted-by":"crossref","unstructured":"Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, et al. Hemoglobin HbA1c and mean glucose in patients with type 1 diabetes: analysis of data from the Juvenile Diabetes Research Foundation continuous glucose monitoring randomized trial, Diabetes Care 34 (2011) 540\u2013544.","DOI":"10.2337\/dc10-1054"},{"key":"10.1016\/j.clinbiochem.2020.06.009_b0150","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/dme.12285","article-title":"Paediatric estimated average glucose in children with type 1 diabetes","volume":"31","author":"O'Riordan","year":"2014","journal-title":"Diabet. Med."},{"key":"10.1016\/j.clinbiochem.2020.06.009_b0155","doi-asserted-by":"crossref","unstructured":"Diabetes Research in Children Network (DirecNet) Study Group, Wilson DM,Kollman. Relationship of HBA1C to glucose concentrations in children with type 1 diabetes: assessments by high-frequency glucose determinations by sensors. Diabetes Care 31 (2008) 381\u2013385.","DOI":"10.2337\/dc07-1835"},{"key":"10.1016\/j.clinbiochem.2020.06.009_b0160","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2337\/dc09-1498","article-title":"Estimated average glucose and self-monitored mean blood glucose are discordant estimates of glycemic control","volume":"33","author":"Hempe","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinbiochem.2020.06.009_b0165","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.2337\/dc12-2711","article-title":"Ethnic differences in glycemic markers in patients with type 2 diabetes","volume":"36","author":"Wolffenbuttel","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinbiochem.2020.06.009_b0170","doi-asserted-by":"crossref","first-page":"994","DOI":"10.2337\/dc17-0636","article-title":"The fallacy of average: how using HbHbA1c alone to assess glycemic control can be misleading","volume":"40","author":"Beck","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinbiochem.2020.06.009_b0175","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.2337\/dc16-0042","article-title":"Are there clinical implications of racial differences in HbHbA1c? A difference, to be a difference, must make a difference","volume":"39","author":"Selvin","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinbiochem.2020.06.009_b0180","doi-asserted-by":"crossref","first-page":"95","DOI":"10.7326\/M16-2596","article-title":"T1D Exchange Racial Differences Study Group. Racial Differences in the Relationship of Glucose Concentrations and Hemoglobin HbA1c Levels","volume":"167","author":"Bergenstal","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.clinbiochem.2020.06.009_b0185","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1515\/CCLM.2010.083","article-title":"Disparity in estimated average glucose due to different hemoglobin HbA1c methods and hemoglobin S trait","volume":"48","author":"Zhu","year":"2010","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.clinbiochem.2020.06.009_b0190","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1177\/0145721709336298","article-title":"A randomized comparison of the terms estimated average glucose versus hemoglobin HBA1C","volume":"35","author":"Brick","year":"2009","journal-title":"Diabetes Educ"},{"key":"10.1016\/j.clinbiochem.2020.06.009_b0195","doi-asserted-by":"crossref","unstructured":"P. Kazemian, F.M. Shebl, N. McCann, R.P. Walensky, D.J. Wexler, Evaluation of the cascade of diabetes care in the United States, 2005-2016. JAMA Int. Med. 179 (2019) 1376\u20131385 [Epub ahead of print].","DOI":"10.1001\/jamainternmed.2019.2396"},{"key":"10.1016\/j.clinbiochem.2020.06.009_b0200","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.diabres.2017.12.004","article-title":"Achievement of guideline targets for blood pressure, lipid, and glycaemic control in type 2 diabetes: a meta-analysis","volume":"137","author":"Khunti","year":"2018","journal-title":"Diabetes Res. Clin. Pract."}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912020304240?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912020304240?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T15:56:32Z","timestamp":1757865392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009912020304240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":40,"alternative-id":["S0009912020304240"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2020.06.009","relation":{},"ISSN":["0009-9120"],"issn-type":[{"type":"print","value":"0009-9120"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Usefulness of estimated average glucose (eAG) in glycemic control and cardiovascular risk reduction","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2020.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}